Insight Pharmaceuticals has voluntarily recalled a single lot of its Nostrilla oxymetazoline hydrochloride nasal spray due to possible contamination with Burkholderia cepacia bacteria. Nostrilla is available without prescription, and lot #11G075, which consisted of 34,092 1/2-oz bottles, was distributed in US retail stores and pharmacies. According to Insight, it has received no reports of illness at this time.
Insight CEO Gary Downing commented: “It is our commitment to our customers to provide them with products they can rely on as safe and effective for their FDA-approved uses. Through our standard testing procedures and protocols, we discovered the potential presence of a bacterial contaminant in one lot of Nostrilla, and reported it to the FDA. Consumer safety is our #1 priority, and we’ll take all necessary action to ensure Nostrilla, as well as all of our products, comply with FDA regulations and requirements.”
Read the Insight press release.
